NasdaqCM - Nasdaq Real Time Price ? USD Eyenovia, Inc. (EYEN) Follow Compare 0.4866 -0.0136 (-2.72%) At close: November 7 at 4:00 PM EST 0.4900 +0.00 (+0.70%) After hours: November 7 at 5:15 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the relea GlobeNewswire ? 16 hours ago EYEN -2.72% Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet? Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives Additional presentation at the American Academy of Optometry summarizes a Phase 4 study of Mydcombi demonstrating that clinically relevant mydriasis can be achieved with a half-dose per eye NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, toda GlobeNewswire ? 15 days ago EYEN -2.72% Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the?American Academy of Ophthalmology (AAO) 2024 Expo Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular surgeryNEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held October 19-21, in Chicago. The presentation will detail the results of a s GlobeNewswire ? 22 days ago EYEN -2.72% Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now Eyenovia (EYEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. Zacks ? 24 days ago EYEN -2.72% Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges Despite a significant net loss, Eyenovia Inc (EYEN) progresses with innovative technologies and promising collaborations in the ophthalmic market. GuruFocus.com ? 29 days ago EYEN -2.72% Eyenovia Announces Commencement of Manufacturing of its?Advanced, Second Generation Optejet Device The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of its FDA-approved mydriasis product, Mydcombi, a key step in the approval process for its state-of-the-art Gen-2 Optejet dispensing platform. Mydcombi will GlobeNewswire ? last month EYEN -2.72% Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8,695,653 shares of its common stock (or common stock equivalents in lieu thereof) and warrants GlobeNewswire ? last month EYEN -2.72% Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol’s prescribing informationNEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery. “The commercial launch of Cl GlobeNewswire ? last month EYEN -2.72% Formosa Pharma ships APP13007 ophthalmic drug to US APP13007 is the first US FDA-approved ophthalmic solution featuring the super-potent corticosteroid clobetasol propionate. Pharmaceutical Technology ? last month EYEN -2.72% Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced that its strategic partner, Taiwan-based Formosa Pharmaceuticals (TWO:6838), was granted a Taiwan Export License for clobetasol propionate ophthalmic suspension 0.05% (“clobe GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transitionNEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced the appointment of experienced finance and accounting executive Andrew Jones as Chief Financial Officer. Mr. Jones brings to the Eyenovia team more than 30 years of divers GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia Announces Closing of Public Offering NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The gross proceeds to Eyenovia from this Offering are approximately $5.14 million, before deducting the placement agent’s fees and other offering expenses payable by Eyenovia. Eyenovia intends to use the net proceeds fro GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia Announces Pricing of $5.14 Million Public Offering NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering"). The closing of the Offering is expected to occur on or about August 22, 2024, subject to the satisfaction of customary closing conditions. All of the securities in the Offering are being sold by Eyenovia. Dawson James Securities, I GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia, Inc. Announces Proposed Public Offering NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offering are to be offered by Eyenovia. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, o GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know Eyenovia (EYEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Zacks ? 2 months ago EYEN -2.72% Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi? (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, clobetasol propionate ophthalmic suspension, 0.05% for postsurgical inflammation and pain, and developing the Optejet? device for use both in connection with its own drug-device therapeutic product for pediatric progressive myopia and dry eye as well as out-licensing for addition GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates Eyenovia (EYEN) delivered earnings and revenue surprises of -5.88% and 98.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago EYEN -2.72% Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update Following FDA consultation, announced plans for validation of the Gen-2 Optejet? device and 2025 regulatory submission with Mydcombi? as lead product Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for analysis in Q4 Commenced sales activities with focus on Mydcombi in 260+ offices and preparations for launch of clobetasol propionate ophthalmic suspension 0.05%, the first new ophthalmic steroid to enter the market in 15 years Announc GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Monday, August 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at GlobeNewswire ? 2 months ago EYEN -2.72% Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. Product-candidate would incorporate new steroid with the Optejet? for the millions of dry eye patients who experience periodic flare-upsNEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that it has signed a non-binding agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) whereby the companies will co-develop a formulation GlobeNewswire ? 2 months ago EYEN -2.72% Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return EYEN S&P 500 YTD -76.61% +25.23% 1-Year -62.71% +36.81% 3-Year -88.07% +27.15%
